Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q4 FY22 results · Jan–Mar 2022
Alivus Life Sciences reported revenue from operations of ₹514.06 crore and net profit of ₹98.90 crore for Q4 FY22 (Jan–Mar 2022), on a standalone basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 514.06 | — | — | 522.50 | −1.6% |
| Other income | 5.09 | — | — | 3.53 | +44.2% |
| Total income | 519.15 | — | — | 526.03 | −1.3% |
| Profit before tax | 137.63 | — | — | 139.80 | −1.6% |
| Net profit for the period | 98.90 | — | — | 103.71 | −4.6% |
| EPS, basic (₹) | 8.07 | — | — | 8.65 | −6.7% |
| Net margin (%) | 19.2 | — | 19.8 |
Standalone
- Filed with BSE
- 21 Apr 2022, 15:18 IST
- Board meeting
- 20 Apr 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE